Research project
Susceptibility of Patient derived xenograph (PDX) models of Leukemia/lymphoma to cerdulatinib alone or in combination with venetoclax or rituximab
-
Other researchers:
-
Research funder:Portola Pharmaceuticals
-
Status:Not active
